InvestorPlace - Stock market News, Stock Advice & Trading Tips
Special purpose acquisition companies (SPACs) have been the talk of Wall Street for more than a year now. And although 2020 was deemed the “year of the SPAC,” 2021 also has welcomed a few of their own. That said, business mogul Richard Branson and 23andMe are getting in on the action.
Source: Sergei Bachlakov / Shutterstock.comWhat do these two have going on, and why should investors care?
Let’s dive in and take a closer look at the latest SPAC move featuring Richard Branson and 23andMe.
- Branson’s Virgin Acquisition Group (NYSE:VGAC) announced on June 10 that its shareholders voted to approve a previously announced merger agreement with 23andMe.
- Additionally, according to the release, more than “87% of the votes cast at the Special Meeting were in favor of the approval of the merger agreement.”
- In turn, the agreement allows 23andMe to hit Wall Street.
- Shares will begin trading on June 17 via the Nasdaq exchange under the “ME” stock ticker.
- The agreement initially occurred back in February with a value of around $3.5 billion.
- In that release, Branson and 23andMe said their hope is to “revolutionize personalized healthcare and therapeutic development through human genetics.”
Shares of VGAC stock rose nearly 10% the day of the announcement but are down about 4.7% as of Tuesday afternoon.
On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Nick Clarkson is a web editor at InvestorPlace.
More From InvestorPlace
Stock Prodigy Who Found NIO at $2… Says Buy THIS Now
It doesn’t matter if you have $500 in savings or $5 million. Do this now.
Top Stock Picker Reveals His Next Potential 500% Winner
The post VGAC Stock: Everything You Need to Know About Richard Branson, 23andMe and This Week’s SPAC Merger appeared first on InvestorPlace.